Legacy BioDesign LLC, Johnstown, CO, USA.
Department of Chemistry, Colorado State University, Fort Collins, CO, USA.
Pharm Res. 2024 Jul;41(7):1301-1367. doi: 10.1007/s11095-024-03726-x. Epub 2024 Jun 27.
There have been significant advances in the formulation and stabilization of proteins in the liquid state over the past years since our previous review. Our mechanistic understanding of protein-excipient interactions has increased, allowing one to develop formulations in a more rational fashion. The field has moved towards more complex and challenging formulations, such as high concentration formulations to allow for subcutaneous administration and co-formulation. While much of the published work has focused on mAbs, the principles appear to apply to any therapeutic protein, although mAbs clearly have some distinctive features. In this review, we first discuss chemical degradation reactions. This is followed by a section on physical instability issues. Then, more specific topics are addressed: instability induced by interactions with interfaces, predictive methods for physical stability and interplay between chemical and physical instability. The final parts are devoted to discussions how all the above impacts (co-)formulation strategies, in particular for high protein concentration solutions.'
近年来,自我们上次综述以来,在液态下蛋白质的配方和稳定化方面取得了重大进展。我们对蛋白质-赋形剂相互作用的机制理解有所增加,使得人们能够以更合理的方式开发配方。该领域已朝着更复杂和更具挑战性的配方发展,例如高浓度配方以允许皮下给药和共配方。虽然发表的大部分工作都集中在单抗上,但这些原则似乎适用于任何治疗性蛋白质,尽管单抗显然具有一些独特的特征。在这篇综述中,我们首先讨论化学降解反应。接下来是关于物理不稳定性问题的部分。然后,更具体的主题被讨论:与界面相互作用引起的不稳定性、物理稳定性的预测方法以及化学和物理不稳定性之间的相互作用。最后部分专门讨论了上述所有内容如何影响(共)配方策略,特别是对于高蛋白浓度溶液。